National Alliance of Breast Cancer Organizations Relaunches Website

Publication
Article
OncologyONCOLOGY Vol 15 No 11
Volume 15
Issue 11

With the aim of making its website more comprehensive and supportive of women with breast cancer, the National Alliance of Breast Cancer Organizations (NABCO) has expanded and redesigned www.nabco.org. The new version, which became

With the aim of making itswebsite more comprehensive and supportive of women with breast cancer, theNational Alliance of Breast Cancer Organizations (NABCO) has expanded andredesigned www.nabco.org. The new version, which became available on October 24,2001, is part of the organization’s ongoing effort to educate both patientsand clinicians about good breast health, provide the latest breast cancerinformation, and foster community support.

User-Friendly Features

Among the new features added to the website is the NABCORecurrence Project. Despite the wealth of information available on breastcancer, very few sources address recurrent or advanced breast cancer. Thisfeature will offer research updates, sources for care and support, and resourcesand facts about the detection and treatment of recurrent and advanced breastcancer. Novartis, a major sponsor of the website relaunch, provided funding forthe Recurrence Project.

Also available online for the first time is the NABCOBreast Cancer Resource list. Although the print version is in its 15th year ofpublication, the completely updated online version was just added. Thisreference guide contains more than 3,000 breast cancer resources, includingbooks, brochures, booklets, organizations, hotlines, and websites.

Among the website’s other features are an e-mail remindersystem and an online calendar, both of which have been expanded and made moreuser-friendly. The reminder system prompts women to schedule breast exams andmammograms, and the calendar tracks breast cancer conferences, medical meetings,policy- and advocacy-related activities, outreach and fundraising events,corporate and worksite health promotions, and locations for free and low-costscreenings.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content